Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions remain.

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into optimising anti-CD38 antibody-containing quadruplet regimens (quads) for ...

Opens in a new tab or window Daratumumab plus a standard triplet improved minimal residual disease negativity rates in patients with transplant-ineligible multiple myeloma. The quadruplet also ...

Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming the first direct rival to Johnson & Johnson’s big-selling Darzalex.

an antibody directed at CD38 – and BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). The new drug is one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

根据协议条款，复宏汉霖将负责HLX15的研发、生产以及商业化供应，并从交易中获得1.316亿美元，其中3300万美元为交易首付款。此外，复宏汉霖还将获得基于产品年度净销售额的分级特许权使用费。Dr.

which we don't see in the use of Anti-CD38 based antibodies. Other developments in the field of myeloma also include the use of PCMA based therapy. BCMA is B-cell maturation antigen and it is a ...